The drug will be tested as part of a clinical study on 80-40-year-olds infected with the virus, and are in a mild-to-moderate state • "The drug's effect is hopeful"
Another innovative drug will be given to mild to moderate corona patients in Hadassah clinical research: After recently starting Hadassah in a drug trial in Avigan, a drug that came from Japan, and has been proven effective in shortening the duration of the disease and preventing serious patients' deterioration, today (Monday) is expected to be given first treatment in another clinical trial. Hadassah outbreaks.
Corona Questions and Answers // Photo: Ministry of Health
The new treatment, brought to Israel by Prof. Eyal Masheni, director of the Hadassah Research and Development Division, is a drug called Camostat Mesylate, which is approved in Japan for patients with pancreatitis.
With the help of the Hadassah Pharmacy, they were able to bring 7,000 Camyl Mesylate pills to the hospital.
Prof. Masheni: "This is a drug that has been proven in a basic study by a German team of researchers to inhibit the infiltration of the virus into healthy cells of human tissue. An article published several days ago by the prestigious CELL magazine shows that the German research group explicitly demonstrated in culture plates how the virus entered cells. And how the drug can significantly stop the entrance. The drug is approved for use in Japan for other indications and now in the clinical trial will be given to corona patients in Hadassah. "
The experiment was approved by the Helsinki Hospital Commission
"We have designed a well-defined clinical trial whereby those who are in the early stages of the disease will be given a pill to swallow for several days, three times a day. Our first sample group will be 10 patients who will receive the said pill, and for 5 days, when only 40 years old can participate in the trial. 80 who are diagnosed and verified patients of the Corona virus who are mild to moderate in severity.
This experiment will look at the effect of the drug that inspires great hope and great interest in the world. "